C3PO: Cutibacterium Acnes: Triple Prevention in Shoulder Operations

Sponsor
Clinique Générale dAnnecy (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05701475
Collaborator
Centre Hospitalier Annecy Genevois (Other)
156
1
3
8
19.6

Study Details

Study Description

Brief Summary

Patients planned for shoulder surgery will be identified and contacted for participation.

After informed consent is provided, patients will be randomised into one of three groups:

pre-operative cutaneous disinfection with iodine (control group), pre-operative cutaneous and subcutaneous disinfection with iodine (double prevention), and pre-operative cutaneous and subcutaneous disinfection with iodine combined with a skin preparation protocol with benzoyl peroxide gel in the days prior to surgery (triple prevention). Bacterial cultures will be collected during surgery of the surgical field and tissue layers. Culture positivity for Cutibacterium Acnes will be compared between the groups as a primary outcome.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Subcutaneous disinfection
  • Procedure: Benzoyl peroxide preparation
N/A

Detailed Description

Eligible patients will be contacted for participation (see Eligibility Criteria). If subjects meet the inclusion criteria, patients will receive information regarding the study outline, associated risks, and subject rights. Informed consent must be freely given, specific, unambiguous, and may be withdrawn at any time. Subjects must be legally capable of providing consent. Consent will be and recorded in writing and stored for the duration of the study. The target for inclusion was set at 52 patients in each group, of each group 26 will be arthroscopic and 26 open surgery.

Patients will be divided into three groups of equal size:
  • Triple-prevention: Benzoyl peroxide at home, subcutaneous iodine, and cutaneous iodine.

  • Double-prevention: Cutaneous and subcutaneous iodine.

  • Single-prevention (control group): cutaneous iodine.

Simple block randomisation will be used to prevent chronological bias and ensure equal group size. Treatments will be allocated with a 1:1:1 ratio using a block size of 12. Randomisation will be stratified by open or arthroscopic surgery to ensure an equal number in all three groups (3x2x26 patients) Random treatment allocation numbers will be generated and blinded, to be revealed after inclusion.

Benzoyl peroxide:

Patients will be instructed to apply and rub in a 5-cm strip of 5% benzoyl peroxide gel to the shoulder on dry skin in the morning and evening 2 days prior to surgery, 1 day before surgery, and a fifth time in the morning on the day of surgery.

Cutaneous iodine:

Standard pre-operative preparation including cutaneous disinfection with alcoholic iodine, sterile drapes.

Subcutaneous iodine:

Open surgery: after incision down to the fascia of the muscle layer, preparation of the whole subcutaneous layer with povidone-iodine solution will be performed and left acting during 60 seconds before full aspiration and lavage in order to not have swabs drained in povidone-iode (as it could continue to act as antiseptic during culture).

For arthroscopic procedures the disinfection and swab collection protocol will be performed when creating the first portal.

Bacterial culture swabs (n=9) will be taken during surgery from the patients' skin (before disinfection with iodine), subcutaneous tissue (after disinfection if randomised for subcutaneous disinfection), muscular layer, intra-articular/layer of the intervention (for example in case of clavicle surgery from the clavicle), surgeon's glove, outside scalpel, inside scalpel, and the retractors. For the swabs in the operative field, the applicable field is to be swabbed fully for 3 seconds. Each surgeon will follow the clear swab instructions from the microbiologist in order to obtain reliable cultures. Cultures will be analysed by the hospital's medical microbiological laboratory following standard protocol including a standard incubation time of 14 days. Treatment arm will be blinded for the laboratory employees.

Culture positivity between the groups will be analysed using chi-square tests for each culture location. In addition, a two-way ANOVA test will be performed to assess total number of positive cultures per patient. Furthermore, logistic regression models will be used to adjust for several potential confounding factors depending on the number of positive tests in the sample.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
156 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Randomised controlled trialRandomised controlled trial
Masking:
Single (Outcomes Assessor)
Masking Description:
Since the disinfection protocol has to be performed by the patient and care provider, this can not be blinded. However, the laboratory staff will not know which treatment arm the patient was allocated to when assessing the bacterial cultures.
Primary Purpose:
Prevention
Official Title:
Triple Prevention Against Cutibacterium Acnes Using Benzoyl Peroxide Preparation in Addition to Pre-operative Cutaneous and Subcutaneous Iodine in Shoulder Surgery; a Single-blinded, Randomized, Controlled Trial.
Anticipated Study Start Date :
Feb 1, 2023
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Oct 1, 2023

Arms and Interventions

Arm Intervention/Treatment
No Intervention: Control/Single prevention

Standard pre-operative cutaneous disinfection using iodine.

Experimental: Double prevention

Pre-operative cutaneous and subcutaneous disinfection using iodine.

Procedure: Subcutaneous disinfection
After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.

Experimental: Triple prevention

Pre-operative cutaneous and subcutaneous disinfection using iodine and preparation of the skin with benzoyl peroxide in the days prior to surgery.

Procedure: Subcutaneous disinfection
After incision, the subcutaneous tissue will be disinfected for 60 seconds using iodine before continuing the surgical approach.

Procedure: Benzoyl peroxide preparation
In the days prior to surgery, the skin will be prepared using Benzoyl Peroxide gel according to a standardised protocol.

Outcome Measures

Primary Outcome Measures

  1. Cutibacterium Acnes positivity [14 days]

    Cultures taken during surgery positive for Cutibacterium Acnes

Secondary Outcome Measures

  1. Culture positivity with other bacteria [14 days]

    Cultures taken during surgery positive for any type of bacteria

  2. Adherence to pre-operative protocol [1 day]

    Completeness of the pre-operative skin preparation protocol as reported by participants the morning of the intervention

Other Outcome Measures

  1. Adverse reaction to Benzoyl Peroxide [1 day]

    Adverse reactions of any type to Benzoyl Peroxide reported by participants

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients with an indication for all types of surgery at the shoulder joint, acromioclavicular joint, or clavicle, including arthroscopic and open surgery.
Exclusion Criteria:
  • Previous shoulder surgery, history of shoulder infection, antibiotic treatment in the last 6 weeks, allergy or hypersensitivity to one of the disinfecting agents, and patients with laboratory values consistent with a current infection (C-reactive protein, erythrocyte sedimentation rate, leukocyte count).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Clinique Générale d'Annecy Annecy France

Sponsors and Collaborators

  • Clinique Générale dAnnecy
  • Centre Hospitalier Annecy Genevois

Investigators

  • Principal Investigator: Geert A Buijze, MD, PhD, Clinique Générale d'Annecy

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Clinique Générale dAnnecy
ClinicalTrials.gov Identifier:
NCT05701475
Other Study ID Numbers:
  • 2023C3PO-trial
First Posted:
Jan 27, 2023
Last Update Posted:
Jan 27, 2023
Last Verified:
Jan 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Clinique Générale dAnnecy
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 27, 2023